Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NGNE · Entity 5160 | Director | January 16, 2024 | June 16, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 13, 2024 | June 20, 2024 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Chief Operating Officer | September 24, 2026 | September 25, 2026 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Director | May 20, 2026 | May 22, 2026 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | June 09, 2025 | June 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date January 16, 2024 · Filed June 16, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.30 · Expires 2034-01-16 | Direct | 15,400 |
Reported balance
After 2024-01-16 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-01-16 · Grant · Acquired 15,400 · Balance 15,400 F1: This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date.
ROCKET PHARMACEUTICALS, INC.
Report date June 13, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2034-06-13 | Direct | 23,944 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 23,944 · Balance 23,944 F1: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025.
Scholar Rock Holding Corp
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 572,021 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Gift · Disposed 48,034 · Balance 572,021 F1: On September 24, 2026, the reporting person transferred 48,034 shares of the Issuer's Common Stock to the RKW Irrevocable Trust for no consideration. The reporting person's spouse serves as trustee of the RKW Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2: Consists of 0 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. |
| Common StockSEC Table I · non-derivative | IndirectBy RKW Irrevocable Trust | 48,034 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 48,034 F1: On September 24, 2026, the reporting person transferred 48,034 shares of the Issuer's Common Stock to the RKW Irrevocable Trust for no consideration. The reporting person's spouse serves as trustee of the RKW Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 24, 2026, the reporting person transferred 48,034 shares of the Issuer's Common Stock to the RKW Irrevocable Trust for no consideration. The reporting person's spouse serves as trustee of the RKW Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2: Consists of 0 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.
TScan Therapeutics, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2036-05-20 | Direct | 67,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 67,000 · Balance 67,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.
X4 Pharmaceuticals, Inc
Report date June 09, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2025-06-09 transaction · row 1
1 source rowRow 1 · 2025-06-09 · Grant · Acquired 1,500 · Balance 6,000 F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 25, 2026 20:12 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GiftCommon Stock | 48,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-110976 · tm2626188-1_4seq1.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,021 F1 · shares: On September 24, 2026, the reporting person transferred 48,034 shares of the Issuer's Common Stock to the RKW Irrevocable Trust for no consideration. The reporting person's spouse serves as trustee of the RKW Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · balance_after: Consists of 0 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001193125-26-236855 · ownership.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Voting Common Stock · 67,000 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 22:12 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 10,220 | $49.57 | $506,651.39 |
DisclosureSEC source: 0001104659-26-045584 · tm2612274-4_4seq1.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620,055 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 48,034 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:40 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,050 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001996804-26-000002 · wk-form4_1771976400.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,050 Underlying: Common Stock · 12,050 shares Expires 2036-02-20 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 23:05 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 47,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-013578 · tm266077-1_4seq1.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,275 F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. F2 · balance_after: Consists of 33,254 shares of common stock, 147,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. Read SEC document |
| January 13, 2026 Filed Jan 16, 2026 00:57 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 16,746 | $42.70 | $715,054.20 |
DisclosureSEC source: 0001104659-26-004223 · tm263352-3_4seq1.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,254 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units subject to performance- and time-based vesting conditions ("PSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. Each PSU represents the contingent right to receive upon vesting of the PSU, one share of the Issuer's common stock. F2 · shares: (continued) The shares vested pursuant to awards that were granted on April 27, 2025. 50,000 shares subject to this PSU vested on January 12, 2026, with an additional 50,000 shares scheduled to vest on April 27, 2027 and the remaining shares vesting in tranches of a combination of performance-based vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four years, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration. F3 · balance_after: Consists of 33,254 shares of common stock, 100,000 restricted stock units subject to time-based vesting conditions and 450,000 PSUs. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000950170-25-093047 · ownership.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Voting Common Stock · 67,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 12, 2025 Filed Jun 16, 2026 21:31 UTC Amendment | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,050 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001996804-26-000009 · wk-form4a_1781645516.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,050 Underlying: Common Stock · 12,050 shares Expires 2035-06-12 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030500 · wk-form4_1749587415.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| May 02, 2025 Filed May 6, 2025 21:02 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 110,067 | $0.00 Strike: $32.91 | $0.00 |
DisclosureSEC source: 0001104659-25-045117 · tm2513936-4_4seq1.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,067 Underlying: Common Stock · 110,067 shares Expires 2035-05-02 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on April 27, 2026, with the remainder vesting in twelve equal quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Read SEC document |
| April 27, 2025 Filed Apr 29, 2025 22:10 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041464 · tm2513505-7_4seq1.xml · nonDerivative · entry 2 Woods Keith · CIK 0001996804 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 F2 · shares: Represents performance based RSUs subject to performance- and time-based vesting conditions (the "PSUs"). The amount reported herein represents the maximum number of shares of the Issuer's common stock that may be issued under this award. The shares subject to this PSU vest in tranches of a combination of performance vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four years, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration. Read SEC document |
| April 27, 2025 Filed Apr 29, 2025 22:10 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041464 · tm2513505-7_4seq1.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on April 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Read SEC document |
| June 14, 2024 Filed Jun 16, 2026 21:32 UTC Amendment | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 7,700 | $0.00 Strike: $42.59 | $0.00 |
DisclosureSEC source: 0001996804-26-000010 · wk-form4a_1781645522.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2034-06-14 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 23,944 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001140361-24-030730 · form4.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,944 Underlying: Common Stock · 23,944 shares Expires 2034-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:20 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $8.88 | $0.00 |
DisclosureSEC source: 0000950170-24-073696 · ownership.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Voting Common Stock · 47,500 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:12 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027673 · wk-form4_1718136748.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| January 16, 2024 Filed Jun 16, 2026 21:32 UTC Amendment | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,400 | $0.00 Strike: $32.30 | $0.00 |
DisclosureSEC source: 0001996804-26-000011 · wk-form4a_1781645528.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,400 Underlying: Common Stock · 15,400 shares Expires 2034-01-16 F1 · derivative.exercise_date: This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| December 07, 2023 Filed Dec 13, 2023 01:51 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 11,960 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001140361-23-057390 · form4.xml · derivative · entry 2 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,960 Underlying: Common Stock · 11,960 shares Expires 2033-12-07 F2 · derivative.exercise_date: This option represents a right to purchase a total of 11,960 shares of the Issuer's common stock, which will fully vest on December 7, 2024. Read SEC document |
| December 07, 2023 Filed Dec 13, 2023 01:51 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 20,522 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001140361-23-057390 · form4.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,522 Underlying: Common Stock · 20,522 shares Expires 2033-12-07 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,522 shares of the Issuer's common stock, which will vest in equal monthly installments over a three-year period, such that all of the shares underlying this option will be fully vested on December 7, 2026. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 13:20 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $6.74 | $0.00 |
DisclosureSEC source: 0000950170-23-068925 · ownership.xml · derivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Voting Common Stock · 17,500 shares Expires 2033-12-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) December 6, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:02 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034579 · wk-form4_1697659344.xml · nonDerivative · entry 1 Woods Keith · CIK 0001996804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 F1 · shares: Represents a restricted stock units ("RSUs") grant. The RSUs will vest in three equal annual installments commencing on October 16, 2024, subject to the Reporting Person's continued service as a director through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.